The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain

@article{Jaggar1998TheAA,
  title={The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain},
  author={S. Jaggar and F. Hasnie and S. Sellaturay and A. Rice},
  journal={Pain},
  year={1998},
  volume={76},
  pages={189-199}
}
&NA; This study assessed the effects of two N‐acylethanolamides in established rat models of visceral and somatic inflammatory pain. (1) The therapeutic effects of the cannabinoid anandamide and the putative CB2 agonist palmitoylethanolamide were tested in a model of persistent visceral pain (turpentine inflammation of the urinary bladder). Both anandamide (at a dose of 25 mg/kg) and palmitoylethanolamide (at doses of 10–30 mg/kg) were able to attenuate the viscero‐visceral hyper‐reflexia (VVH… Expand
327 Citations
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 90 REFERENCES
Physiological and behavioural effects of the endogenous cannabinoid, arachidonylethanolamide (anandamide), in the rat
  • 79
  • Highly Influential
The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice.
  • 390
  • Highly Influential
Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors
  • 491
  • PDF
Antinociceptive activity of intrathecally administered cannabinoids alone, and in combination with morphine, in mice.
  • 192
  • Highly Influential
Spinal and supraspinal components of cannabinoid-induced antinociception.
  • 226
  • Highly Influential
Peripheral opioid receptors mediating antinociception in inflammation. Evidence for involvement of mu, delta and kappa receptors.
  • 516
...
1
2
3
4
5
...